Pfizer, Bristol-Myers eye Onyx deal as first-round bids loom

Street talk about Big Pharma bidders for Onyx Pharmaceuticals ($ONXX) puts Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) in the hunt, with biotech giant Amgen ($AMGN) still leading the charge. Novartis ($NVS), Sanofi ($SNY), GlaxoSmithKline ($GSK) and Biogen Idec ($BIIB) are said to have bowed out. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.